Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenith DrugsNSE:ZENITHDRUG -1.21%45 EBITDA Margin % is 9.87% as of Mar. 2026, which is 0% below its 10-year median of 9.90. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 45/100. The stock has 8 warning signs investors should review. Among 961 Drug Manufacturers companies, Zenith Drugs ranks worse than 56.4% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zenith Drugs's EBITDA for the
six
months ended in Mar. 2026 was ₹92 Mil. Zenith Drugs's Revenue for the
six
months ended in Mar. 2026 was ₹930 Mil. Therefore, Zenith Drugs's EBITDA margin for the quarter that ended in Mar. 2026 was 9.87%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zenith Drugs EBITDA Margin % Related Terms
Zenith Drugs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zenith Drugs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ZENITHDRUG vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Drugs EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zenith Drugs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Drugs (NSE:ZENITHDRUG) has a EBITDA Margin % of 9.87% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zenith Drugs and its competitors. This is near median its historical median of 9.90. Over the past decade, Zenith Drugs' EBITDA Margin % has ranged from 7.95 to 12.61. According to the industry distribution chart, Zenith Drugs ranks #542 out of 961 companies in the Drug Manufacturers industry, placing it in the top 56.4%.
Is Zenith Drugs' EBITDA Margin % too high?
Zenith Drugs' current EBITDA Margin % of 9.87% is near median its 10-year median of 9.90. Over the past 10 years, this metric has ranged from a low of 7.95 to a high of 12.61. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Zenith Drugs' value of 9.87% is 21% below this industry median. Based on the distribution chart, Zenith Drugs ranks #542 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zenith Drugs has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zenith Drugs ranks #542 out of 961 companies for EBITDA Margin %. This places Zenith Drugs in the lower half of its industry. The industry median EBITDA Margin % is 12.49. Zenith Drugs' value of 9.87% is 21% below this benchmark. Historically, Zenith Drugs' own EBITDA Margin % has ranged from 7.95 to 12.61 over the past decade. While the company's 10-year median is 9.90 vs. the industry median of 12.49, Zenith Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenith Drugs's current EBITDA Margin % of 9.87% is 21% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zenith Drugs and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Drugs's current EBITDA Margin % is 9.87%, which is near median its own 10-year median of 9.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current EBITDA Margin % of 9.87%. The current EBITDA Margin % is 9.87%, which is near median its 10-year median of 9.90 and 21% below the Drug Manufacturers industry median of 12.49. Zenith Drugs' overall GF Score™ is 45/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current EBITDA Margin % is 9.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
45GF Score
Get the complete analysis for NSE:ZENITHDRUG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZENITHDRUG has been successfully added to your 
